MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Biogen Inc

Open

SectorGezondheidszorg

118.15 -1.02

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

117.21

Max

119.98

Belangrijke statistieken

By Trading Economics

Inkomsten

-122M

267M

Verkoop

-15M

2.5B

K/W

Sectorgemiddelde

10.42

57.333

EPS

3.44

Winstmarge

10.865

Werknemers

7,605

EBITDA

-158M

536M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+51.84% upside

Dividenden

By Dow Jones

Volgende Winsten

1 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-4.2B

17B

Vorige openingsprijs

119.17

Vorige sluitingsprijs

118.15

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Biogen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 sep 2024, 11:00 UTC

Top Nieuws

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29 mei 2024, 15:56 UTC

Winsten
Acquisities, Fusies, Overnames

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

Peer Vergelijking

Prijswijziging

Biogen Inc Prognose

Koersdoel

By TipRanks

51.84% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 181.46 USD  51.84%

Hoogste 265 USD

Laagste 121 USD

Gebaseerd op 29 Wall Street-analisten die 12-maands prijsdoelen bieden voor Biogen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

29 ratings

14

Buy

15

Hold

0

Sell

Technische score

By Trading Central

118.83 / 119.99Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.